Latest News

Dr. Reddy’s Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the U.S. Market




HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of DIPRIVAN (propofol) Injectable Emulsion, USP, approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy’s is committed to providing affordable and innovative medicines for healthier lives. T

Source link

Related posts

Double whammy for grieving spouses with sleep problems

Newsemia

Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer’s Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases

Newsemia

Novel program that provides comprehensive care for Turner syndrome earns national recognition

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World